Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial

References

• Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Brod, M., & Rowland, C. R. (2004). Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2(1), 12. https://doi.org/10.1186/1477-7525-2-12
   PubMedGoogle Scholar
• Brown, N., & Panksepp, J. (2009). Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses, 72(3), 333–337. https://doi.org/10.1016/j.mehy.2008.06.048
   PubMed Web of Science ®Google Scholar
• Bruce, R. D., Merlin, J., Lum, P. J., Ahmed, E., Alexander, C., Corbett, A. H., Foley, K., Leonard, K., Treisman, G. J., & Selwyn, P. (2017). 2017 HIVMA of IDSA clinical practice guideline for the management of chronic pain in patients living with HIV. Clinical Infectious Diseases, 65(10), e1–e37. https://doi.org/10.1093/cid/cix636
   PubMed Web of Science ®Google Scholar
• Caldeiro, R. M., Malte, C. A., Calsyn, D. A., Baer, J. S., Nichol, P., Kivlahan, D. R., & Saxon, A. J. (2008). The association of persistent pain with out-patient addiction treatment outcomes and service utilization. Addiction, 103(12), 1996–2005. https://doi.org/10.1111/j.1360-0443.2008.02358.x
   PubMed Web of Science ®Google Scholar
• Chang, R. C., Rota, C., Glover, R. E., Mason, R. P., & Hong, J. S. (2000). A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: A study by electron paramagnetic resonance spectroscopy. Brain Research, 854(1–2), 224–229. https://doi.org/10.1016/S0006-8993(99)02267-2
   PubMed Web of Science ®Google Scholar
• Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., & Wu, A. W. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12(3), 255–266. https://doi.org/10.1080/09540120050042891
   PubMed Web of Science ®Google Scholar
• Chishinga, N., Kinyanda, E., Weiss, H. A., Patel, V., Ayles, H., & Seedat, S. (2011). Validation of brief screening tools for depressive and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Psychiatry, 11(1), 75. https://doi.org/10.1186/1471-244x-11-75
   PubMedGoogle Scholar
• de Boer, I. M., Prins, J. M., Sprangers, M. A., Smit, C., & Nieuwkerk, P. T. (2011). Self-reported symptoms among HIV-lnfected patients on highly active antiretroviral therapy in the ATHENA cohort in The Netherlands. HIV Clinical Trials, 12(3), 161–170. https://doi.org/10.1310/hct1203-161
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-Movaghar, A., & Larney, S. (2019). Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. The Lancet, 394(10208), 1560–1579. https://doi.org/10.1016/S0140-6736(19)32229-9
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Larance, B., Mathers, B., Azim, T., Kamarulzaman, A., Mattick, R., Panda, S., Toufik, A., Tyndall, M., Wiessing, L., Wodak, A., & on behalf of the Reference Group to the United Nations on HIV and Injecting Drug Use. (2008). Benefits and risks of pharmaceutical opioids: Essential treatment and diverted medication; A global review of availability, extra-medical use, injection and the association with HIV. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Pharmaceutical%20opioid%20injection.pdf
   Google Scholar
• Dobalian, A., Tsao, J. C., & Duncan, R. P. (2004). Pain and the use of outpatient services among persons with HIV: Results from a nationally representative survey. Medical Care, 42(2), 129–138. https://doi.org/10.1097/01.mlr.0000108744.45327.d4
   PubMed Web of Science ®Google Scholar
• Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for prescribing opioids for chronic pain – United States, 2016. MMWR. Recommendations and Reports, 65(1), 1–49. https://doi.org/10.15585/mmwr.rr6501e1
   PubMed Web of Science ®Google Scholar
• Gekker, G., Lokensgard, J. R., & Peterson, P. K. (2001). Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug and Alcohol Dependence, 64(3), 257–263. https://doi.org/10.1016/S0376-8716(01)00140-5
   PubMed Web of Science ®Google Scholar
• Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. BMC Public Health, 11(1), 770. https://doi.org/10.1186/1471-2458-11-770
   PubMed Web of Science ®Google Scholar
• Hansen, L., Penko, J., Guzman, D., Bangsberg, D. R., Miaskowski, C., & Kushel, M. B. (2011). Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. Journal of Pain and Symptom Management, 42(6), 893–902. https://doi.org/10.1016/j.jpainsymman.2011.02.026
   PubMed Web of Science ®Google Scholar
• Hoy, D., March, L., Brooks, P., Blyth, F., Woolf, A., Bain, C., Williams, G., Smith, E., Vos, T., Barendregt, J., Murray, C., Burstein, R., & Buchbinder, R. (2014). The global burden of low back pain: Estimates from the global burden of disease 2010 study. Annals of the Rheumatic Diseases, 73(6), 968–974. https://doi.org/10.1136/annrheumdis-2013-204428
   PubMed Web of Science ®Google Scholar
• Hoy, D. G., Smith, E., Cross, M., Sanchez-Riera, L., Blyth, F. M., Buchbinder, R., Woolf, A. D., Driscoll, T., Brooks, P., & March, L. M. (2015). Reflecting on the global burden of musculoskeletal conditions: Lessons learnt from the global burden of disease 2010 study and the next steps forward. Annals of the Rheumatic Diseases, 74(1), 4–7. https://doi.org/10.1136/annrheumdis-2014-205393
   PubMed Web of Science ®Google Scholar
• Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience, 28(1), 20–29. https://doi.org/10.1111/j.1460-9568.2008.06321.x
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board. (2010). Narcotic drugs: Estimated world requirements for 2011—Statistics for 2009 United Nations. https://www.drugsandalcohol.ie/14771/1/INCB_Narcotic_drugs_publication_2010%5B1%5D.pdf
   Google Scholar
• Jiao, J. M., So, E., Jebakumar, J., George, M. C., Simpson, D. M., & Robinson-Papp, J. (2016). Chronic pain disorders in HIV primary care: Clinical characteristics and association with healthcare utilization. Pain, 157(4), 931–937. https://doi.org/10.1097/j.pain.0000000000000462
   PubMed Web of Science ®Google Scholar
• Johansen, K. G. V., Tarp, S., Astrup, A., Lund, H., Pagsberg, A. K., & Christensen, R. (2017). Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. PLoS ONE, 12(8), Article e0183821. https://doi.org/10.1371/journal.pone.0183821
   Web of Science ®Google Scholar
• Kalyadina, S. A., Ionova, T. I., Ivanova, M. O., Uspenskaya, O. S., Kishtovich, A. V., Mendoza, T. R., Guo, H., Novik, A., Cleeland, C. S., & Wang, X. S. (2008). Russian brief pain inventory: Validation and application in cancer pain. Journal of Pain and Symptom Management, 35(1), 95–102. http://www.sciencedirect.com/science/article/pii/S0885392407005660 https://doi.org/10.1016/j.jpainsymman.2007.02.042
   PubMed Web of Science ®Google Scholar
• Kazis, L. E., Miller, D. R., Clark, J. A., Skinner, K. M., Lee, A., Ren, X. S., Spiro, A., 3rd, Rogers, W. H., & Ware, J. E., Jr. (2004). Improving the response choices on the veterans SF-36 health survey role functioning scales: Results from the Veterans Health Study. Journal of Ambulatory Care Management, 27(3), 263–280. https://doi.org/10.1097/00004479-200407000-00010
   PubMedGoogle Scholar
• Kazis, L. E., Miller, D. R., Clark, J., Skinner, K., Lee, A., Rogers, W., Spiro, A., 3rd, Payne, S., Fincke, G., Selim, A., & Linzer, M. (1998). Health-related quality of life in patients served by the Department of Veterans affairs: Results from the Veterans Health Study. Archives of Internal Medicine, 158(6), 626–632. https://doi.org/10.1001/archinte.158.6.626
   PubMed Web of Science ®Google Scholar
• Larson, M. J., Paasche-Orlow, M., Cheng, D. M., Lloyd-Travaglini, C., Saitz, R., & Samet, J. H. (2007). Persistent pain is associated with substance use after detoxification: A prospective cohort analysis. Addiction, 102(5), 752–760. https://doi.org/10.1111/j.1360-0443.2007.01759.x
   PubMed Web of Science ®Google Scholar
• Liu, B., Du, L., & Hong, J. S. (2000). Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. Journal of Pharmacology and Experimental Therapeutics, 293(2), 607–617.
   PubMed Web of Science ®Google Scholar
• Liu, S. L., Li, Y. H., Shi, G. Y., Chen, Y. H., Huang, C. W., Hong, J. S., & Wu, H. L. (2006). A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. Journal of the American College of Cardiology, 48(9), 1871–1879. https://doi.org/10.1016/j.jacc.2006.07.036
   PubMed Web of Science ®Google Scholar
• Merlin, J. S., Westfall, A. O., Raper, J. L., Zinski, A., Norton, W. E., Willig, J. H., Gross, R., Ritchie, C. S., Saag, M. S., & Mugavero, M. J. (2012). Pain, mood, and substance abuse in HIV: Implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. Journal of Acquired Immune Deficiency Syndromes, 61(2), 164–170. https://doi.org/10.1097/QAI.0b013e3182662215
   PubMed Web of Science ®Google Scholar
• Merlin, J. S., Zinski, A., Norton, W. E., Ritchie, C. S., Saag, M. S., Mugavero, M. J., Treisman, G., & Hooten, W. M. (2014). A conceptual framework for understanding chronic pain in patients with HIV. Pain Practice, 14(3), 207–216. https://doi.org/10.1111/papr.12052
   PubMed Web of Science ®Google Scholar
• Namisango, E., Harding, R., Atuhaire, L., Ddungu, H., Katabira, E., Muwanika, F. R., & Powell, R. A. (2012). Pain among ambulatory HIV/AIDS patients: Multicenter study of prevalence, intensity, associated factors, and effect. The Journal of Pain, 13(7), 704–713. https://doi.org/10.1016/j.jpain.2012.04.007
   PubMed Web of Science ®Google Scholar
• Needle, R., Fisher, D. G., Weatherby, N., Chitwood, D., Brown, B., Cesari, H., Booth, R., Williams, M., Watters, J., Andersen, M., & Braunstein, M. (1995). Reliability of self-reported HIV risk behaviors of drug users. Psychology of Addictive Behaviors, 9(4), 242–250. https://doi.org/10.1037/0893-164X.9.4.242
   Web of Science ®Google Scholar
• National Institute on Alcohol Abuse and Alcoholism. (2007). Helping Patients Who Drink Too Much: A Clinician's Guide—Updated. National Institutes of Health.
   Google Scholar
• Parker, R., Stein, D. J., & Jelsma, J. (2014). Pain in people living with HIV/AIDS: A systematic review. Journal of the International AIDS Society, 17(1), 18719. https://doi.org/10.7448/IAS.17.1.18719
   PubMedGoogle Scholar
• Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1(3), 385–401. https://doi.org/10.1177/014662167700100306
   Web of Science ®Google Scholar
• Sobell, L. C., & Sobell, M. B. (1995). Alcohol Timeline Followback (TLFB) Users’ Manual. Addiction Research Foundation.
   Google Scholar
• Spitzer, R. L., Kroenke, K., Williams, J. B., & Lowe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092
   PubMed Web of Science ®Google Scholar
• Surratt, H. L., Kurtz, S. P., Levi-Minzi, M. A., Cicero, T. J., Tsuyuki, K., & O’Grady, C. L. (2015). Pain treatment and antiretroviral medication adherence among vulnerable HIV-positive patients. AIDS Patient Care and STDs, 29(4), 186–192. https://doi.org/10.1089/apc.2014.0104
   PubMed Web of Science ®Google Scholar
• Tsao, J. C., Dobalian, A., & Stein, J. A. (2005). Illness burden mediates the relationship between pain and illicit drug use in persons living with HIV. Pain, 119(1-3), 124–132. https://doi.org/10.1016/j.pain.2005.09.023
   PubMed Web of Science ®Google Scholar
• Tsao, J. C., Stein, J. A., Ostrow, D., Stall, R. D., & Plankey, M. W. (2011). The mediating role of pain in substance use and depressive symptoms among multicenter AIDS cohort study (MACS) participants. Pain, 152(12), 2757–2764. https://doi.org/10.1016/j.pain.2011.08.024
   PubMed Web of Science ®Google Scholar
• Tsui, J. I., Cheng, D. M., Coleman, S. M., Blokhina, E., Bridden, C., Krupitsky, E., & Samet, J. H. (2013). Pain is associated with heroin use over time in HIV-infected Russian drinkers. Addiction, 108(10), 1779–1787. https://doi.org/10.1111/add.12274
   PubMed Web of Science ®Google Scholar
• Tsui, J. I., Cheng, D. M., Coleman, S. M., Lira, M. C., Blokhina, E., Bridden, C., Krupitsky, E., & Samet, J. H. (2014). Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, russia. Drug and Alcohol Dependence, 144, 87–92. https://doi.org/10.1016/j.drugalcdep.2014.08.013
   PubMed Web of Science ®Google Scholar
• Tsui, J. I., Cheng, D. M., Quinn, E., Bridden, C., Merlin, J. S., Saitz, R., & Samet, J. H. (2016). Pain and mortality risk in a cohort of HIV-infected persons with alcohol Use disorders. AIDS and Behavior, 20(3), 583–589. https://doi.org/10.1007/s10461-015-1206-8
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services. National Health Interview Survey, 1997 (ICPSR 2954). National Center for Health Statistics. Retrieved September 10, 2019, from https://doi.org/10.3886/ICPSR02954.v2
   Google Scholar
• Wang, X., Douglas, S. D., Peng, J. S., Metzger, D. S., O’Brien, C. P., Zhang, T., & Ho, W. Z. (2006). Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. Journal of Leukocyte Biology, 79(6), 1166–1172. https://doi.org/10.1189/jlb.1105642
   PubMed Web of Science ®Google Scholar
• Weatherby, N. L., Needle, R., Cesari, H., Booth, R., McCoy, C. B., Watters, J. K., Williams, M., & Chitwood, D. D. (1994). Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Evaluation and Program Planning, 17(4), 347–355. http://www.sciencedirect.com/science/article/pii/0149718994900353 https://doi.org/10.1016/0149-7189(94)90035-3
   Web of Science ®Google Scholar
• Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Quality of Life Research, 6(6), 481–493. http://www.ncbi.nlm.nih.gov/pubmed/9330549 https://doi.org/10.1023/A:1018451930750
   PubMed Web of Science ®Google Scholar
• Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism, 65(2), 529–538. https://doi.org/10.1002/art.37734
   PubMed Web of Science ®Google Scholar
• Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2
   PubMed Web of Science ®Google Scholar